Clinical Protocol & Data Management (CPDM) functions at Moffitt Cancer Center (MCC) include 1) trial design, development, and conduct; 2) oversight of safety and compliance; 3) ensuring data quality and education of personnel; and 4) appropriate accrual of women and minorities. A collaborative team of approximately 190 CPDM professionals provides centralized management and support of all types of clinical trials, including investigator-initiated (IITs), industry or other sponsor-initiated, Experimental Therapeutics Clinical Trials Network (ET-CTN), and National Clinical Trials Network (NCTN). CPDM support for members includes: protocol development; budget development and contracting; regulatory and IND/IDE management; protocol activation; patient enrollment; coordination of study-related patient care; research drug administration and care services; correlative science (pharmacokinetics/pharmacodynamics) sample coordination; data collection and reporting; monitoring of IIT studies and data and safety monitoring through the Protocol Monitoring Committee (PMC) and Data Safety & Monitoring (DSM) Committee; audit preparation and coordination; minority outreach and navigation for accrual to clinical trials; clinical trials management system (CTMS, OnCore) administration and reporting; staff workload management; and staff education and training. During the review period (FY2011-2015), the CPDM team successfully accrued and coordinated a combined total of 11,851 patients to clinical interventional trials (therapeutic, prevention, and supportive care), including accrual at affiliate sites. CPDM provides centralized safety and compliance oversight to members through timely monitoring of investigator-initiated interventional trials, coordination of the PMC, and corporate compliance audits of MCC clinical research trials, policies, and processes. Results of monitoring and audits are utilized by the PMC for comprehensive review. MCC has developed and maintains proactive efforts to provide programs and services to women, minorities, and other underserved populations through culturally and linguistically relevant care, education, and internal and community outreach. Faculty members conduct research on minority health disparities, informing these programs and services. In addition, the ACD for Clinical Science and the VP of Diversity and Community Relations co-lead a multi-disciplinary Minority Clinical Research Committee to address issues related to minority accrual at MCC. CPDM resources are closely integrated in these efforts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-22
Application #
9868924
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
22
Fiscal Year
2020
Total Cost
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Persi, Erez; Duran-Frigola, Miquel; Damaghi, Mehdi et al. (2018) Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 9:2997
Kim, Youngchul; Pierce, Christine M; Robinson, Lary A (2018) Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer 18:843
Chen, Yan; Zhu, Jin-Yi; Hong, Kwon Ho et al. (2018) Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors. ACS Chem Biol 13:582-590
Rosenberger, Albert; Hung, Rayjean J; Christiani, David C et al. (2018) Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. Int Arch Occup Environ Health 91:937-950
Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75
Kahen, Elliot John; Brohl, Andrew; Yu, Diana et al. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget 9:22571-22585
Gonzalez, Brian D; Small, Brent J; Cases, Mallory G et al. (2018) Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer 124:499-506
Puri, Sonam; Hyland, Kelly A; Weiss, Kristine Crowe et al. (2018) Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer 26:2911-2918
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350

Showing the most recent 10 out of 1254 publications